Lexaria Bioscience Corp.
LEXX Healthcare Biotechnology
Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024. In the quarter to May 2026, revenue fell 89.1%, EPS grew 61.9% and free cash flow grew 53.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow LEXX
Lexaria Bioscience Corp. (LEXX) EV/Sales
As of 16 October 2026, Lexaria Bioscience Corp. (LEXX) trades at a EV/Sales of 2.4×. Over the past ten years it has ranged from −3.3× (July 2020) to 155× (March 2024); the current reading is higher than 17% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 19.9× | (76.14%) |
| FY2024 | 83.4× | 240.79% |
| FY2023 | 24.5× | (44.85%) |
| FY2022 | 44.4× | 105.45% |
| FY2021 | 21.6× | 908.84% |
| FY2020 | 2.1× | (76.52%) |
| FY2019 | 9.1× | (50.33%) |
| FY2018 | 18.4× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Feb 2026 | 22.4× | 12.69% |
| Aug 2025 | 19.9× | (8.04%) |
| May 2025 | 21.6× | (40.95%) |
| Feb 2025 | 36.7× | (37.85%) |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| EVGN Evogene Ltd. compare | −2.8× |
| ENVB Enveric Biosciences, Inc. compare | −0.1× |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| TRAW Traws Pharma, Inc. compare | 0.3× |
| LEXX Lexaria Bioscience Corp. | 2.4× |
| TCRT Alaunos Therapeutics, Inc. compare | 1,552× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)